Fertility preservation and minimizing reproductive damage in cancer survivors

Expert Review of Anticancer Therapy

Volumn 7, Issue 7, 2007, Pages 989-1001

  Mitwally, Mohamed F M ^a,b,c  

^a Canadian American Reproductive Medicine (CAREM)   (Canada)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c Reproductive Medicine and Fertility Center (RMFC)   (United States)

Author keywords

Cancer; Chemotherapy; Fertility; Preservation; Radiotherapy; Reproduction

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CLOMIFENE CITRATE; CYCLOPHOSPHAMIDE; ESTROGEN; FOLLITROPIN; GONADORELIN ANTAGONIST; GONADOTROPIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SEX HORMONE; TAMOXIFEN; TIBOLONE; TRIPTORELIN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; CYTOTOXICITY; DISEASE RESISTANCE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FERTILITY; FERTILIZATION IN VITRO; GENITAL SYSTEM DISEASE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFERTILITY; LYMPHOMA; MENSTRUATION; MONOTHERAPY; NONHUMAN; OVARIECTOMY; OVARY FUNCTION; OVARY INSUFFICIENCY; OVARY METASTASIS; OVULATION; OVULATION INDUCTION; PATIENT SAFETY; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; RADIATION DOSE; RADIATION INJURY; RISK REDUCTION; SPERM PRESERVATION; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY; TESTIS TUMOR; TISSUE PRESERVATION; TISSUE TRANSPLANTATION; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

FEMALE; HUMANS; INFERTILITY, FEMALE; INFERTILITY, MALE; MALE; NEOPLASMS; REPRODUCTIVE TECHNIQUES, ASSISTED; SURVIVORS;

EID: 34547548611     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.989     Document Type: Article

References (113)

1. Mitwally MFM. Effect of cancer and cancer treatment on human reproduction. Expert Rev. Anticancer Ther. 7(6) 811-822 (2007).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
3. Kim SS, Soules MR, Battaglia DE. Follicular development, ovulation, and corpus luteum formation in cryopreserved human ovarian tissue after xenotransplantation. Fertil. Steril. 78, 77-82 (2002).
4. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med. Pediatr. Oncol. 33, 29-33 (1999).
5. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy - protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur. J. Haematol. 75, 77-82 (2005).
6. Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum. Reprod. Update 4, 248-259 (1998).
7. Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Ovarian tissue and oocyte cryopreservation. Fertil. Steril. 86(5 Suppl.), S142-S147 (2006).
8. Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24(18), 2917-2931 (2006).
9. Dargent D, Brun JL, Remy I. Pregnancies following radical trachelectomy for invasive cervical cancer. Gynecol. Oncol. 52, 105-108 (1994).
10. Grant P. Radical trachelectomy. Aust. N. Z. J. Obstet. Gynaecol. 46(5), 372-374 (2006).
11. Gershenson DM. Fertility-sparing surgery for malignancies in women. J. Natl Cancer Inst. Monogr. 34, 43-47 (2005).
12. Kay TA, Renninson JN, Shepherd JH, Taylor MJ. Successful pregnancy following radical trachelectomy and in vitro fertilisation with ovum donation. Br. J. Obstet. Gynecol. 113, 965-966 (2006).
13. Hertel H, Kohler C, Grund D et al.; German Association of Gynecologic Oncologists (AGO). Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol. Oncol. 103, 506-511 (2006).
14. Plante M, Lau S, Brydon L, Swenerton K, LeBlanc R, Roy M. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol. Oncol. 101, 367-370 (2006).
15. McCall ML, Keaty EC, Thompson JD. Conservation of ovarian tissue in the treatment of carcinoma of the cervix with radical surgery. Am. J. Obstet. Gynecol. 75, 590-600 (1958).
16. Morice P, Thiam-Ba R, Castaigne D et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum. Reprod. 13, 660-663 (1998).
17. Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am. J. Obstet. Gynecol. 188, 367-370 (2003).
18. Bidzinski M, Lemieszczuk B, Zielinski J. Evaluation of the hormonal function and features of the ultrasound picture of transposed ovary in cervical cancer patients after surgery and pelvic irradiation. Eur. J. Gynaecol. Oncol. 14(Suppl.), 77-80 (1993).
19. Scott SM, Schlaff W. Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin's disease. J. Pediatr. Adolesc. Gynecol. 8(5), 355-357 (2005).
20. Martin JR, Kodaman P, Oktay K, Taylor HS. Ovarian cryopreservation with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. Fertil. Steril. 87(1), 189.E5-E7 (2007).
21. Morice P, Castaigne D, Haie-Meder C et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. Fertil. Steril. 70, 956-960 (1998).
22. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum. Reprod. Update. 10, 251-266 (2004).
23. Morice P, Juncker L, Rey A et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil. Steril. 74, 743-748 (2000).
24. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol. Cell. Endocrinol. 187, 93-105 (2002).
25. Pereyra Pacheco B, Mendez Ribas JM, Milone G et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol. Oncol. 81, 391-397 (2001).
26. Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother. Pharmacol. 19, 159-162 (1987).
27. Emons G, Grundker C, Gunthert AR et al. GnRH antagonist in the treatment of gynecological and breast cancers. Endocr. Relat. Cancer 10, 291-299 (2003).
28. Mullen P, Scott WN, Miller WR. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br. J. Cancer 63, 930-932 (1991).
29. Jonat W. The role of LHRH analogs in premenopausal breast cancer. In: GnRH Analogues: the State of the Art 2001. A Summary of the 6th International Symposium on GnRH Analogues in Cancer and Human Reproduction. Lunenfeld B (Ed.). Parthenon Publishing Group, NY, USA, 205-217 (2002).
30. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 23, 7555-7564 (2005).
31. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martinez de Osaba MJ, Balasch J. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil. Steril. 87(3), 702-705 (2007).
32. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum. Reprod. 19(6), 1294-1299 (2004).
33. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil. Steril. 83(5), 1333-1338 (2005).
34. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 58, 849-851 (1981).
35. Whitehead E, Shalet SM, Blackledge G et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 52, 988-993 (1983).
36. Montz FJ, Wolff AJ, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res. 51, 2124-2126 (1991).
37. Familiari G, Caggiati A, Nottola SA. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum. Reprod. 8, 2080-2087 (1993).
38. Tilly JL. Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells. Toxicol. Lett. 102, 497-501 (1998).
39. Tilly JL. Apoptosis and ovarian function. Rev. Reprod. 1, 162-172 (1996).
40. Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev. Biol. 213, 1-17 (1999).
41. Johnson DH, Linde R, Hainsworth JD et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 65, 832-836 (1985).
42. Brennemann W, Brensing KA, Leipner N et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-tryptophan-6 luteinizing hormone releasing hormone. Clin. Investig. 72, 838-842 (1994).
43. Kreuser ED, Hetzel WD, Hautmann R et al. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm. Metab. Res. 22, 494-498 (1990).
44. Dafopoulos K, Griesinger G, Schultze-Mosgau A et al. Cumulative pregnancy rate after ICSI with cryopreserved testicular tissue in non-obstructive azoospermia. Reprod. Biomed. Online 10, 461-466 (2005).
45. Brook PF, Radford JA, Shalet SM et al. Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. Fertil. Steril. 75, 269-274 (2001).
46. Geary S, Moon YS. The human embryo in vitro: recent progress. J. Reprod. Med. 51(4), 293-302 (2006).
47. Michelmann HW, Nayudu P. Cryopreservation of human embryos. Cell Tissue Bank. 7(2), 135-141 (2006).
48. Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod. Technol. 10, 244-247 (2000).
49. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum. Reprod. 188, 1588-1597 (2003).
50. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J. Soc. Gynecol. Investig. 11(6), 406-415 (2004).
51. Tulandi T, Martin J, Al-Fadhli R et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril. 85, 1761-1765 (2006).
52. Okray K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 23, 4347-4353 (2005).
53. Oktay K, Hourvitz A, Sabin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. 91, 3885-3890 (2006).
54. Levi Setti PE, Albani E, Novara PV, Cesana A, Morreale G. Cryopreservation of supernumerary oocytes in IVF/ICSI cycles. Hum. Reprod. 21, 370-375 (2006).
55. Borini A, Sciajno R, Bianchi V, Sereni E, Flamigni C, Coticchio G. Clinical outcome of oocyte cryopreservation after slow cooling with a protocol utilizing a high sucrose concentration. Hum. Reprod. 21, 512-517 (2006).
56. Shaw JM, Oranratnachai A, Trounson AO. Fundamental cryobiology of mammalian oocytes and ovarian tissue. Theriogenology 53, 59-72 (2000).
57. Baka SG, Toth TL, Veeck LL, Jones HW Jr, Muasher SJ, Lanzendorf SE. Evaluation of the spindle apparatus of in-vitro matured human oocytes following cryopreservation. Hum. Reprod. 10, 1816-1820 (1995).
58. Pickering SJ, Braude PR, Johnson MH, Cant A, Currie J. Transient cooling to room temperature can cause irreversible disruption of the meiotic spindle in the human oocyte. Fertil Steril. 54, 102-108 (1990).
59. Matson PL, Graefling J, Junk SM, Yovich JL, Edirisinghe WR. Cryopreservation of oocytes and embryos: use of a mouse model to investigate effects upon zona hardness and formulate treatment strategies in an in-vitro fertilization programme. Hum. Reprod. 12, 1550-1553 (1997).
60. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Curr. Opin. Obstet. Gynecol. 17(1), 21-26 (2005).
61. Donnez J, Martinez-Madrid B, Jadoul P, Van Langendonckt A, Demylle D, Dolmans MM. Ovarian tissue cryopreservation and transplantation: a review. Hum. Reprod. Update 2(5), 519-535 (2006).
62. Jeremias E, Bedaiwy MA, Gurunluoglu R, Biscotti CV, Siemionow M, Falcone T. Heterotopic autotransplantation of the ovary with microvascular anastomosis: a novel surgical technique. Fertil. Steril. 77(6), 1278-1282 (2002).
63. Bedaiwy MA, Falcone T. Ovarian tissue banking for cancer patients: reduction of post-transplantation ischaemic injury: intact ovary freezing and transplantation. Hum. Reprod. 19(6), 1242-1244 (2004).
64. Bedaiwy MA, Hussein MR, Biscotti C, Falcone T. Cryopreservation of intact human ovary with its vascular pedicle. Hum. Reprod. 21(12), 3258-3269 (2006).
65. Oktay K, Newton H, Aubard Y, Salha O, Gosden RG. Cryopreservation of immature human oocytes and ovarian tissue: an emerging technology? Fertil. Steril. 69, 1-7 (1998).
66. Maltaris T, Dimmler A, Muller A, Hoffmann I, Beckmann MW, Dittrich R. Comparison of two freezing protocols in an open freezing system for cryopreservation of rat ovarian tissue. J. Obstet. Gynaecol. Res. 32, 273-279 (2006).
67. Newton H, Aubard Y, Rutherford A, Sharma V, Gosden R. Low temperature storage and grafting of human ovarian tissue. Hum. Reprod. 11, 1487-1491 (1996).
68. Donnez J, Dolmans MM, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364, 1405-1410 (2004).
69. Meirow D, Levron J, Eldar-Geva T et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N. Engl. J. Med. 353, 318-321 (2005).
70. Oktay K. Spontaneous conceptions and live birth afier heterotopic ovarian transplantation: is there a germline stem cell connection? Hum. Reprod. 21(6), 1345-1348 (2006).
71. Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363, 837-840 (2004).
72. Eppig JJ, O'Brien MJ. Development in vitro of mouse oocytes from primordial follicles. Biol, Reprod. 54, 197-207 (1996).
73. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum. Reprod. 1, 81-87 (1986).
74. Weissman A, Gotlieb L, Colgan T, Jurisicova A, Greenblatt EM, Casper RF. Preliminary experience with subcutaneous human ovarian cortex transplantation in the NOD-SCID mouse. Biol. Reprod. 60(6), 1462-1467 (1999).
75. Maltaris T, Kaya H, Hoffmann I, Mueller A, Beckmann MW, Dittrich R. Comparison of xenografting in SCID mice and LIVE/DEAD assay as a predicior of the developmental potential of cryopreserved ovarian tissue. In Vivo 20, 11-16 (2006).
76. Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res. 322, 125-132 (2005).
77. Shaw JM, Bowles J, Koopman P, Wood EC, Trounson AO. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum. Peprod. 11, 1668-1673 (1996).
78. Seshadri T, Gook D, Lade S et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br. J. Cancer 10, 1007-1010 (2006).
79. Mueller A, Maltaris T, Dimmler A, Hoffmann I, Beckmann MW, Dittrich R. Development of sex cord stromal tumors after heterotopic transplantation of cryopreserved ovarian tissue in rats. Anticancer Res. 25, 4107-4111 (2005).
80. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 6, 209-218 (2005).
81. Chung K, Irani J, Knee G et al. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur. J. Obstet. Gynecol. Reprod. Biol. 113(Suppl. 1), S7-S11 (2004)
82. Lass A, Akagbosu F, Abusheikha N et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years' experience. Hum. Reprod. 13, 3256-3261 (1998).
83. Foley SJ, De Winter P, McFarlane JP et al. Storage of sperm and embryos. Cryopreservation of sperm should be offered to men with testicular cancer. Br. Med. J. 313, 1078 (1996).
84. Schover LR, Brey K, Lichtin A et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J. Clin. Oncol. 20, 1880-1889 (2002).
85. Schover LR, Rybicki LA, Martin BA et al. Having children after cancer: a pilot survey of survivors' attitudes and experiences. Cancer 86, 697-709 (1999).
86. Glaser AW, Phelan L, Crawshaw M et al. Fertility preservation in adolescent males with cancer in the United Kingdom: a survey of practice. Arch. Dis. Child. 89, 736-737 (2004).
87. Agarwal A, Ranganathan P, Kattal N et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil, Steril. 81, 342-348 (2004).
88. Audrins P, Holden CA, McLachlan RI et al. Semen storage for special purposes at Monash IVF from 1977 to 1997. Fertil. Steril. 72, 179-181 (1999).
89. Blackhall FH, Atkinson AD, Maaya MB et al. Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. Br. J. Cancer 87, 381-384 (2002).
90. Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer - criteria change. Fertil. Steril. 58, 1024-1027 (1992).
91. Shin D, Lo KC, Lipshultz LI. Treatment options for the infertile male with cancer. J. Natl. Cancer Inst. Monogr. 34, 48-50 (2005).
92. Bennett CJ, Seager SW, McGuire EJ. Electroejaculation for recovery of semen after retroperitoneal lymph node dissection: case report. J. Urol. 137, 513-515 (1987).
93. Hultling C, Rosenlund B, Tornblom M et al. Transrectal electroejaculation in combination with in-vitro fertilization: an effective treatment of anejaculatory infertility after testicular cancer. Hum. Reprod. 10, 847-850 (1995).
94. Meseguer M, Garrido N, Remohi J et al. Testicular sperm extraction (TESE) and ICSI in patients with permanent azoospermia after chemotherapy. Hum. Reprod. 18, 1281-1285 (2003).
95. Kliesch S, Behre HM, Jurgens H et al. Cryopreservation of semen from adolescent patients with malignancies. Med. Pediatr. Oncol. 26, 20-27 (1996).
96. Bahadur G, Ling KL, Hart R et al. Semen production in adolescent cancer patients. Hum. Reprod. 17, 2654-2656 (2002).
97. Schrader M, Muller M, Straub B, Miller K. Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy - a new therapy option. Asian J. Androl. 4, 9-15 (2002).
98. Schmiegelow ML, Sommer P. Carlsen E, Sonksen JO, Schmiegelow K, Muller JR. Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. J. Pediatr. Hematol. Oncol. 20, 429-430 (1998).
99. Hawkins MM, Draper GJ, Smith RA. Cancer among 1,348 offspring of survivors of childhood cancer. Int. J. Cancer 43, 975-978 (1989).
100. O'Donovan M. An evaluation of chromatin condensation and DNA integrity in the spermatozoa of men with cancer before and after therapy. Andrologia 37, 83-90 (2005).
101. Arnon J, Meirow D, Lewis-Roness H et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum. Reprod. Update 7, 394-403 (2001).
102. Thomson AB, Campbell AJ, Irvine DC et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 360, 361-367 (2002).
103. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. Proc. Natl Acad. Sci. USA 91, 11298-11302 (1994).
104. Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for preservation of male fertility. J. Natl. Cancer Inst. Monogr. 34, 51-56 (2005).
105. Brinster CJ, Ryu BY, Avarbock MR, Karagenc L, Brinster R-L, Orwig KE. Restoration of fertility by germ cell transplantation requires effective recipient preparation. Biol. Reprod. 69, 412-420 (2003).
106. Schlatt S, Rosiepen G, Weinbauer GF, Rolf C, Brook PF, Nieschlag E. Germ cell transfer into rat, bovine, monkey and human testes. Hum. Reprod. 14, 144-150 (1999).
107. Jahnukainen K, Hou M, Petersen C, Setchell B, Soder O. Intratesticular transplantation of testicular cells from leukemic rats causes transmission of leukemia. Cancer Res. 61, 706-710 (2001).
108. Frederickx V, Michiels A, Goossens E, De Block G, Van Steirteghem AC, Tournaye H. Recovery, survival and functional evaluation by transplantation of frozen-thawed mouse germ cells. Hum. Reprod. 19, 948-953 (2004).
109. Tesarik J, Bahceci M, Ozcan C, Greco E, Mendoza C. Restoration of fertility by in vitro spermatogenesis. Lancet 353, 555-556 (1999).
110. Lee DR, Kim KS, Yang YH et al. Isolation of male germ stem cell-like cells from testicular tissue of non-obstructive azoospermic patients and differentiation into haploid male germ cells in vitro. Hum. Reprod. 21, 471-476 (2006).
111. Kvist K, Thorup J, Byskov AG, Hoyer PE, Mollgard K, Yding Andersen C. Cryopreservation of intact testicular tissue from boys with cryptorchidism. Hum. Reprod. 21, 484-491 (2006).
112. Keros V, Hultenby K, Borgstrom B, Fridstrom M, Jahnukainen K, Hovatta O. Methods of cryopreservation of testicular tissue with viable spermatogonia in prepubertal boys undergoing gonadotoxic cancer treatment. Hum. Reprod. 22, 1384-1395 (2007).
113. Wyns C, Curaba M, Martinez-Madrid B, Van Langendonckr A, Francois-Xavier W, Donnez J. Spermatogonial survival after cryopreservation and short-term orthotopic immature human cryptorchid testicular tissue grafting to immunodeficient mice. Hum. Reprod. 22, 1603-1611 (2007).